During Wednesday’s Afternoon trade, Shares of QUALCOMM Incorporated (NASDAQ:QCOM), lost -1.49% to $65.99.
Semiconductor Manufacturing International Corporation, China’s largest and most advanced semiconductor foundry; Huawei, a leading global information and communications technology (ICT) solutions provider; imec, one of the world-leading nanoelectronics research and development (R&D) centers; and Qualcomm Global Trading Pte. Ltd., an associate of Qualcomm Incorporated, one of the world’s largest fabless semiconductor vendors, held a signing ceremony at the Great Hall of the People, to declare the formation of SMIC Advanced Technology Research & Development (Shanghai) Corporation, an equity joint venture company. The joint venture company will focus on R&D towards next generation CMOS logic technology and build China’s most advanced integrated circuit (IC) development R&D platform.
His Majesty (H.M.) King Philippe of Belgium is visiting China in the framework of several cooperation agreements between China and Belgium related to cutting-edge technology. A Chinese leader and H.M. King Philippe of Belgium witnessed the signing ceremony of the joint investment.
SMIC Advanced Technology R&D (Shanghai) Corporation will be majority owned by SMIC, while Huawei, imec, and Qualcomm will be minority shareholders. The current focus will be on developing 14nm logic technology. Dr. Tzu-Yin Chiu, Chief Executive Officer and Executive Director of SMIC will be the legal representative, Dr. Yu Shaofeng, Vice President of SMIC will be the general manager.
In the first phase, the joint venture company will develop 14 nanometer CMOS technology for mass production, which will be based on imec’s state-of-the-art knowhow in advanced semiconductor processing technology. The new R&D project will be done at SMIC’s production line.
SMIC will have the rights to license the required intellectual property rights on the mass production technologies of advanced nodes developed by the joint venture company, enabling these technologies to be applied to SMIC’s current and future range of products and serve SMIC’s business with other companies. This can improve the overall level of China’s IC technologies, and is predictable to facilitate the mass production of 16/14nm ICs in China by 2020, which is one of the aims set by the National IC Industry Development Outline. In the future, companies in China’s IC manufacturing industry, universities and colleges, and research institutions will continue working together on this platform to further enhance the core competitiveness of the industry.
Semiconductor Manufacturing International Corporation (“SMIC”) (NYSE: SMI; SEHK: 981) is one of the leading semiconductor foundries in the world and the largest and most advanced foundry in mainland China.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States. The company operates through three segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Planned Initiatives (QSI).
Shares of E. I. du Pont de Nemours and Company (NYSE:DD), inclined -2.42% to $66.85, during its current trading session.
DuPont Protection Technologies (DuPont), declared the signing of extrajudicial settlement agreements in two counterfeit situations involving fake DuPont(TM) Nomex(R) protective apparel supplied to the oil and gas industry in Southeast Asia and Central Europe. The infringement of the DuPont trademark and mislabeling of protective apparel jeopardized the safety of industrial workers in the regions.
- Safety Depot (PT DTS Nusantara) — Safety Depot of Indonesia admitted to having sold counterfeit products through its Safety Depot outlets serving the oil and gas industry that infringed on DuPont trademarks, counting DuPont(TM) Nomex(R) protective apparel. Under the settlement signed on June 1, 2015, Safety Depot was forced to cease all use of the DuPont brands, remove all labeling from existing inventory, and issue a public apology, which has been accomplished. Please refer to the attachments labeled “Public Apology Published 14 June 2015, Tribun Kaltim, Page 3″ and “English Translation of the Public Apology Published 14 June 2015, Tribun Kaltim, Page 3.”
- DeLUX (SM, S.R.O.) and ASTONA (SM and Lubomir Mlček) — In this case, brought against a manufacturer of protective apparel in Slovakia, garments sold to the oil and gas industry marked with a “NOME” label and claiming to be composed of 93 percent Nomex(R) fiber were tested and discovered to contain no Nomex(R). The settlement, signed on March 20, 2015, comprised of an order for DeLUX and ASTONA to cease and refrain from using their NOME mark due to the confusing similarity to the DuPont(TM) Nomex(R) brand. In addition, the companies committed to cease all infringing use of the DuPont(TM) Nomex(R) brand, and remove and destroy all misleading labels.
E. I. du Pont de Nemours and Company operates as a science and technology based company worldwide. The company’s Agriculture segment offers corn hybrid, soybean, canola, sunflower, sorghum, inoculants, seed products, wheat, rice, herbicides, fungicides, and insecticides.
Finally, Teva Pharmaceutical Industries Limited (NYSE:TEVA), lost -0.45%, and is now trading at $59.53.
Teva Pharmaceutical Industries Limited, declared the launch of PainMatters.com, a new resource designed to assist healthcare professionals and people affected by pain navigate the complex pain care landscape. Pain affects more Americans than diabetes, heart disease and cancer combined and while prescription pain medications are an important component of pain administration, the reality is these products are prone to abuse and misuse. A new survey conducted on behalf of Teva in partnership with the American Academy of Pain Administration and U.S. Pain Foundation broadly found:
- Healthcare professionals and people affected by pain recognize their personal responsibility in addressing prescription drug abuse;
- Some healthcare professionals and people affected by pain are uncomfortable talking with each other about the issue;
- They also agree information and resources are critical in assisting address prescription drug abuse.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
